Key Findings
North America ophthalmic drugs market was valued at $XX million in 2018 and is expected to reach $XX million by 2027 growing at a CAGR of 3.66% during the forecast period of 2019-2027. The ophthalmic drugs and devices market is driven by factors like increase in FDA approvals which gives a boost in the adoption of drugs and devices and rise in surgeries in ophthalmology market due to the high dominance of refractive errors.

Market Insights
The prevalence of blindness and vision impairment and other eye-related disorders is expected to increase rapidly among all age group, gender and racial group in North America. The increase in geriatric population, rise in the number of eye disorders, increase in healthcare expenditure and rise in adoption of minimally invasive surgeries have contributed to the growth of the market in North America.

Well-known drugs are going off patent and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology.

Competitive Insights
Global ophthalmic drugs market has a large number of market players but the market is dominated by companies like Cipla Pharmaceuticals, Sun Pharmaceuticals Industries, Ltd., Valeant, Apollo Endosurgery, Bayer, Johnson and Johnson, Regeneron, Pfizer Inc., Eyegate Pharmaceuticals, Abbott Laboratories, Novartis AG, Roche Holding AG, Allergan Inc., Senju Pharmaceutical Co., Ltd., GlaxoSmithKline, and Merck & Co.